<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02941835</url>
  </required_header>
  <id_info>
    <org_study_id>N16PRB</org_study_id>
    <secondary_id>NL59561.031.16</secondary_id>
    <nct_id>NCT02941835</nct_id>
  </id_info>
  <brief_title>Preoperative Breast Irradiation</brief_title>
  <acronym>PROBI</acronym>
  <official_title>Preoperative Breast Irradiation, the PROBI Trial. A Phase I/II Feasibility Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PROBI is a phase I/II trial assessing the feasibility of preoperative whole breast
      irradiation in female patients with low to intermediate risk breast cancer, who undergo
      breast conserving therapy, including a boost dose of irradiation.

      An additional goal of this study is to assess tumor response to radiotherapy, by imaging
      modalities (PET-CT and MRI) and pathology
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2018</start_date>
  <completion_date type="Anticipated">June 2027</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative surgical complications</measure>
    <time_frame>within six weeks after surgery</time_frame>
    <description>postoperative complication will be scored by a specific list</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiological response</measure>
    <time_frame>6 weeks post-radiation</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological response</measure>
    <time_frame>at surgery</time_frame>
    <description>surgery specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cosmetic outcome</measure>
    <time_frame>1,3 and 5 years post-treatment</time_frame>
    <description>cosmesis will be scored by physician by questionnaire and cosmesis will be cored by patient by questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>gene expression profiles</measure>
    <time_frame>6 weeks</time_frame>
    <description>at start a biopsy will be taken and compared to the surgical specimen at 6 weeks post treatment</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>radiation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>intervention: pre-operative breast irradiation of 21 fx of 2.2Gy and boost 2.66Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>pre-operative irradiation</intervention_name>
    <description>pre-operative whole breast irradiation of 21 fx of 2.2Gy and boost of 2.66Gy</description>
    <arm_group_label>radiation</arm_group_label>
    <other_name>radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven invasive breast carcinoma

          -  cT1-2N0 breast cancer

          -  cM0

          -  Indication for an additional boost to the tumor bed, i.e.:

          -  female patients ≤ 50 years AND/OR

          -  histological grade III carcinoma AND/OR

          -  lymph angio invasion

          -  planned breast conserving surgery (without neo-adjuvant systemic therapy)

          -  Ability to undergo irradiation and surgery

          -  Signed written informed consent

        Exclusion Criteria:

          -  prior surgery or radiotherapy for the protocol tumor

          -  neoadjuvant chemotherapy or hormonal therapy

          -  planned oncoplastic reduction mammoplasty

          -  cTis

          -  no indication for an additional boost to the tumor bed

          -  extensive calcifications on mammagram (Birads 3,4 or 5)

          -  cT3-4 and/or cN1-3 invasive carcinoma

          -  distant metastasis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Astrid Scholten, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antoni van Leeuwenhoek</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Astrid Scholten, MD, PhD</last_name>
    <phone>+31 20 512 9111</phone>
    <email>a.scholten@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicola Russell, MD, PhD</last_name>
    <phone>+31 20 512 9111</phone>
    <email>n.russell@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Scholten, MD, PhD</last_name>
      <phone>+31 20 152 9111</phone>
      <email>a.scholten@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Nicola Russell, MD, PhD</last_name>
      <phone>+31 20 152 9111</phone>
      <email>n.russell@nki.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, Schinagl D, Oei B, Rodenhuis C, Horiot JC, Struikmans H, Van Limbergen E, Kirova Y, Elkhuizen P, Bongartz R, Miralbell R, Morgan D, Dubois JB, Remouchamps V, Mirimanoff RO, Collette S, Collette L; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015 Jan;16(1):47-56. doi: 10.1016/S1470-2045(14)71156-8. Epub 2014 Dec 9. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6.</citation>
    <PMID>25500422</PMID>
  </reference>
  <reference>
    <citation>Donker M, Straver ME, Wesseling J, Loo CE, Schot M, Drukker CA, van Tinteren H, Sonke GS, Rutgers EJ, Vrancken Peeters MJ. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015 Feb;261(2):378-82. doi: 10.1097/SLA.0000000000000558.</citation>
    <PMID>24743607</PMID>
  </reference>
  <reference>
    <citation>Egro FM, Pinell-White X, Hart AM, Losken A. The use of reduction mammaplasty with breast conservation therapy: an analysis of timing and outcomes. Plast Reconstr Surg. 2015 Jun;135(6):963e-971e. doi: 10.1097/PRS.0000000000001274.</citation>
    <PMID>26017612</PMID>
  </reference>
  <reference>
    <citation>Jones HA, Antonini N, Hart AA, Peterse JL, Horiot JC, Collin F, Poortmans PM, Oei SB, Collette L, Struikmans H, Van den Bogaert WF, Fourquet A, Jager JJ, Schinagl DA, Wárlám-Rodenhuis CC, Bartelink H. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol. 2009 Oct 20;27(30):4939-47. doi: 10.1200/JCO.2008.21.5764. Epub 2009 Aug 31.</citation>
    <PMID>19720914</PMID>
  </reference>
  <reference>
    <citation>van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002 Dec 19;347(25):1999-2009.</citation>
    <PMID>12490681</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2016</study_first_submitted>
  <study_first_submitted_qc>October 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2016</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pre-operative radiotherapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

